Trials / Unknown
UnknownNCT03159559
PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes
A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is undertaken to determine if intravenous Lipo-PGE1 therapy would improve coronary microvascular perfusion in patients with ischemic heart disease by CMRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lipo-PGE1 | Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-12-01
- Completion
- 2018-03-01
- First posted
- 2017-05-18
- Last updated
- 2017-05-18
Source: ClinicalTrials.gov record NCT03159559. Inclusion in this directory is not an endorsement.